Encontrados 3 documentos, a visualizar página 1 de 1
Prognostic value of MGMT promoter methylation in glioblastoma patients treated ...
Costa, BM; Caeiro, C; Guimarães, I; Martinho, O; Jaraquemada, T; Augusto, I; Castro, l; Osório, L; Linhares, P; Honavar, M; Resende, M; Nabiço, RGlioblastoma (GBM) is the most common and aggressive primary brain tumor. The identification of novel molecular prognostic markers of GBM has recently been an area of great interest in neuro-oncology. The methylation status of the MGMT gene promoter is currently a promising molecular prognostic marker, but some controversial data have precluded its clinical use. We analyzed MGMT methylation by methylation-speci...
Prognostic value of MGMT promoter methylation in glioblastoma patients treated ...
Costa, BM; Caeiro, C; Guimarães, I; Martinho, O; Jaraquemada, T; Augusto, I; Castro, l; Osório, L; Linhares, P; Honavar, M; Resende, M; Nabiço, RGlioblastoma (GBM) is the most common and aggressive primary brain tumor. The identification of novel molecular prognostic markers of GBM has recently been an area of great interest in neuro-oncology. The methylation status of the MGMT gene promoter is currently a promising molecular prognostic marker, but some controversial data have precluded its clinical use. We analyzed MGMT methylation by methylation-speci...
Gliosarcomas.
Sousa, O; Serviço de Radioterapia, Instituto Português de Oncologia, Porto.; Honavar, M; Fernandes, T; Vieira, E; Lopes, CGliosarcomas are rare tumors of the central nervous system with a poor prognosis. Histologically these tumors are characterized by an admixture of neoplastic glial cells and sarcomatous elements. Due to the scarcity of data in literature, the diagnosis is often missed and treatment is difficult. The authors report three cases of cerebral gliosarcomas and review the literature on this subject. ; Gliosarcomas ar...
| Financiadores do RCAAP | |||||||
|
|
|
|
|
|
||